Table 4.

Multivariable-adjusteda logistic regression analyses of the associations between higher ALb and unfavorable breast cancer clinicopathologic characteristics among Black invasive breast cancer survivors in the Women's Circle of Health Follow-Up Study (2014–2018), by AL measure cohort.

ALAL
measure 1c,d cohortmeasure 2e,f cohort
(n = 181)(n = 323)
Multivariable-adjustedMultivariable-adjusted
OR (95% CI)OR (95% CI)
Tumor grade: poorly differentiated vs. well and moderately differentiated
 AL
  Lower (0–3)1.00 (referent)1.00 (referent)
  Higher (4–8)2.49 (1.28–4.85)1.66 (1.02–2.72)
P = 0.007P = 0.04
Tumor size: ≥2 cm vs. <2 cm
 AL
  Lower (0–3)1.00 (referent)1.00 (referent)
  Higher (4–8)0.93 (0.49–1.79)0.93 (0.49–1.79)
P = 0.38P = 0.38
ER status: ER vs. ER+
 AL
  Lower (0–3)1.00 (referent)1.00 (referent)
  Higher (4–8)1.27 (0.63–2.57)1.52 (0.89–2.57)
P = 0.51P = 0.12
  • Note: Bold values indicate statistical significance.

  • aThe following covariates were included in the multivariable-adjusted regression analyses: (i) age at diagnosis; (ii) birthplace; (iii) marital status; (iv) menopausal status; (v) family history of breast cancer.

  • bThe median AL score among Women's Circle of Health Follow-Up Study participants was 3. Thus, 3 was used as the cutoff point to dichotomize the AL variable.

  • cAL measure 1 was computed on the basis of the following biomarkers: SBP, DBP, waist circumference, glucose level, HDL, triglycerides, total cholesterol and/or LDL, and use of medication to control hypertension, hypercholesterolemia, or diabetes.

  • dIncluded Women's Circle of Health Follow-Up Study participants who were diagnosed with stage I, II, and III cancer in the AL measure 1 group (n = 181).

  • eAL measure 2 was computed on the basis of the following biomarkers: SBP, DBP, waist circumference, glucose level, albumin, eGFR, BMI, and use of medication to control hypertension, hypercholesterolemia, or diabetes.

  • fIncluded Women's Circle of Health Follow-Up Study participants who were diagnosed with stage I, II, and III cancer in the AL measure 2 group (n = 323).